1. Exposure−response modelling for empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in patients with type 2 diabetes. (December 2014) Authors: Riggs, Matthew M.; Seman, Leo J.; Staab, Alexander; MacGregor, Thomas R.; Gillespie, William; Gastonguay, Marc R.; Woerle, Hans J.; Macha, Sreeraj Journal: British journal of clinical pharmacology Issue: Volume 78:Number 6(2014:Dec.) Page Start: 1407 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Population pharmacokinetics of empagliflozin, a sodium glucose cotransporter 2 inhibitor, in patients with type 2 diabetes. (13th August 2013) Authors: Riggs, Matthew M.; Staab, Alexander; Seman, Leo; MacGregor, Thomas R.; Bergsma, Timothy T.; Gastonguay, Marc R.; Macha, Sreeraj Journal: Journal of clinical pharmacology Issue: Volume 53:Number 10(2013:Oct.) Page Start: 1028 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗